Headlines

Abbott Laboratories (ABT) Q4 2025 (USD): Adj. EPS 1.50 (exp. 1.50), Revenue 11.46bln (exp. 11.80bln)

Newsquawk Staff ·

Guidance

  • Q1 adj. EPS 1.12-1.18 (exp. 1.20).
  • FY adj. EPS 5.55-5.80 (exp. 5.68).

What it means

Abbott Laboratories reported Q4 2025 adjusted EPS in line with expectations but missed on revenue, which could raise concerns about demand or pricing power relative to market estimates. Their Q1 and full-year guidance also falls short, suggesting potential headwinds ahead and may impact investor sentiment towards the stock and sector. Monitoring price action and peer performance will be important as analysts recalibrate their outlook based on this performance.

Related headlines